Astorg acquires CordenPharma from ICIG
5 May 2022 – Astorg, a leading European private equity firm, signed a binding agreement for the acquisition of CordenPharma from International Chemical Investors Group (ICIG). As part of the transaction, the founders will take the opportunity to reinvest into in Astorg as partners. The transaction remains subject to customary regulatory approvals.
CordenPharma is a global leading pharmaceutical CDMO (Contract Development & Manufacturing Organisation) with highly differentiated capabilities in Active Pharmaceutical Ingredients, Excipients, and Drug Products. CordenPharma employs more than 2,600 people in 11 manufacturing facilities and one R&D laboratory located across Europe and the US. The company serves more than 250 blue-chip pharma and biotech customers across five technology platforms.
Astorg is a European private equity firm with over EUR 15 billion of assets under management.
Walder Wyss acted as Swiss counsel to Astorg in connection with the transaction. The team was led by Alex Nikitine (Partner, Corporate/M&A) and Dimitrios Berger (Senior Associate, Corporate/M&A) and further included Hugh Reeves (Managing Associate, IP/IT) Boris Räber (Managing Associate, Corporate/M&A), Dzevrije Zendeli (Managing Associate, Employment/Corporate/M&A), Dominik Aerni (Senior Associate, Corporate/M&A), Martina Madonna-Quadri (Senior Associate, Corporate/M&A), Erik Lanz (Associate, Corporate/M&A), Karina Tschon (Associate, Corporate/M&A), Etienne Trandafir (Associate, Real Estate), Milos Karic (Trainee, Corporate/M&A) and Kevin Caratsch (Trainee, Corporate/M&A)